| 영문 | luteinizing hormone(LH) | 한글 | 황체형성호르몬 |
|---|---|---|---|
| 설명 | 여성의 월경은 정해진 순서에 의해 일어나게 된다. 먼저 난포자극호르몬이 뇌에서 분비되어 여성의 난소를 자극하게 되면 난포가 자극받아 난포호르몬(에스트로젠)을 분비하게 되고 이것은 다시 되먹이기 메커니즘 의해 뇌에 작용을 하여 황체화호르몬이 뇌에서 분비되고 이것이 이른바 절정에 이르렀을 때, 난포에서 배란이 일어나게 된다. 이후 난포는 황체로 변하게 되며, 배란된 난자가 수정되지 아니하면, 황체는 황체호르몬(프로게스테론)을 분비한 뒤 퇴화되고 곧 이어 월경이 일어나게 된다. 이 일은 정상적인 대부분의 여성에서 28일을 주기로 일어나며, 대개 황체화호르몬 절정 이후 마지막은 14일로 일정하다고 한다. |
||
| MIF | macrophage inhibitory factor; melanocyte[-stimulating hormone]-inhibiting factor; maximum inspirator... |
|---|---|
| MRF | Markov random field; medical record file; melanocyte-[stimulating hormone]-releasing factor; mesence... |
| MRIF | melanocyte[-stimulating hormone] release-inhibiting factor |
| MSHIF | melanocyte-stimulating hormone-inhibiting factor |
| MSHR | melanocyte stimulating hormone receptor |
| gamma-MSH | gamma- melanocyte stimulating hormone |
|---|---|
| MSH | gamma-melanocyte stimulating hormone |
| GM-CSF | Granulocyte colony-stimulating factor , granulocyte-macrophage colony-stimulating factor |
| G-CSF | Granulocyte-Macrophage Colony-Stimulating Factor , Granulocyte Colony-Stimulating Factor |
| TSH | E--thyroid-stimulating hormone |
| growth hormone-regulating hormone | <endocrinology> Hypothalamic hormones that induce (somatoliberin) or inhibit (somatostatin) the release of growth hormone (somatotropin). (18 Nov 1997) |
|---|---|
| growth hormone-releasing hormone | <endocrinology> Peptide hormone related to the glucagon family, released from the pituitary, acts on the adenohypophysis to release growth hormone. Synonym: somatoliberin, growth hormone-releasing factor. (20 Sep 2002) |
| hormones, hormone substitutes, and hormone antagonists | A collective grouping for both naturally occurring and synthetic hormones, substitutes, and antagonists. (12 Dec 1998) |
| luteinizing hormone-releasing hormone | A hormone that controls sex hormones in men and women. Also called lhrh. (12 Dec 1998) |
| macrophage colony-stimulating factor | <growth factor> A glycoprotein growth factor that causes the committed cell line to proliferate and mature into macrophages. A cytokine synthesised by mesenchymal cells that stimulates pluripotent stem cells of bone marrow into differentiating towards the production of monocytes (mononuclear phagocytes). The compound stimulates the survival, proliferation, and differentiation of haematopoietic cells of the monocyte-macrophage series. It is a disulfide-bonded glycoprotein dimer with a mw of 70 kD and binds to a single class of high affinity receptor which is identical to the product of the c-fms proto-oncogene. See: colony-stimulating factors. Chemical name: Colony-stimulating factor 1 Acronym: M-CSF (12 Dec 1998) |
| receptors, colony-stimulating factor | Cell surface receptors for colony-stimulating factors, local mediators, and hormones that regulate the survival, proliferation, and differentiation of haemopoietic cells. (12 Dec 1998) |
| receptors, granulocyte-colony-stimulating factor | Receptors that bind and internalise granulocyte-colony-stimulating factor. Their mw is believed to be 150 kD. These receptors are found mainly on a subset of myelomonocytic cells. (12 Dec 1998) |
| receptors, granulocyte-macrophage colony-stimulating factor | Receptors that bind and internalise the granulocyte-macrophage stimulating factor. Their mw is believed to be 84 kD. The most mature myelomonocytic cells, specifically human neutrophils, macrophages, and eosinophils, express the highest number of affinity receptors for this growth factor. (12 Dec 1998) |
| receptors, macrophage colony-stimulating factor | Glycoproteins of mw 165 kD which are encoded by the c-fms proto-oncogene. The binding of csf-1 to its receptors activates an intrinsic tyrosine kinase activity resulting in autophosphorylation of the receptors on tyrosine, rapid receptor down-regulation, and phosphorylation of as yet unidentified physiologic substrates that initiate a mitogenic response. (12 Dec 1998) |
| granulocyte-colony-stimulating factor | <growth factor, haematology, oncology> A glycoprotein of 25 kD containing internal disulfide bonds. It induces the survival, proliferation, and differentiation of neutrophilic granulocyte precursor cells and functionally activates mature blood neutrophils. Among the family of colony-stimulating factors, G-CSF is the most potent inducer of terminal differentiation to granulocytes and macrophages of leukaemic myeloid cell lines. A protein that stimulates the growth and maturation of granulocytes. It is used to promote the recovery of the white cells following chemotherapy. See: colony-stimulating factor. Acronym: G-CSF (12 Dec 1998) |
| granulocyte-macrophage colony-stimulating factor | <growth factor, haematology, oncology> An acidic glycoprotein of mw 23 kD with internal disulfide bonds. It is produced in response to a number of inflammatory mediators by mesenchymal cells present in the haemopoietic environment and at peripheral sites of inflammation. It stimulates the production of neutrophilic granulocytes, macrophages, and mixed granulocyte-macrophage colonies from bone marrow cells and can stimulate the formation of eosinophil colonies from foetal liver progenitor cells. It also has some functional activities in mature granulocytes and macrophages. It is used to promote the recovery of the white blood cells following chemotherapy. Chemical name: Colony-stimulating factor 2 See: colony-stimulating factor. Acronym: GM-CSF (12 Dec 1998) |
| colony-stimulating factor | <cell biology> A glycoprotein growth factor that regulates the differentiation of particular cells. These substances act in either paracrine or autocrine fashion on marrow cells, appear to act synergistically and can exert actions on several lines of progenitor cells, and influence end cell function. These lymphokines induce the maturation and proliferation of white blood cells from the primitive cell types present in bone marrow such as the leucocyte, macrophage and monocyte lines. These substances can also be made by recombinant DNA technology for use clinically to speed bone marrow recovery typically following chemotherapy. Acronym: CSF (18 Jul 2002) |
| multi-colony-stimulating factor | <cytokine> Product of mitogen activated T-cells: colony-stimulating factor for bone marrow stem cells and mast cells. A multilineage cell growth factor secreted by lymphocytes, epithelial cells, and astrocytes which stimulates clonal proliferation and differentiation of various types of blood and tissue cells. It is considered one of the haematopoietic colony-stimulating factors. Synonym: multi-CSF Acronym: IL-3 (12 Dec 1998) |
| multipotential colony-stimulating factor | <cytokine> Product of mitogen activated T-cells: colony-stimulating factor for bone marrow stem cells and mast cells. A multilineage cell growth factor secreted by lymphocytes, epithelial cells, and astrocytes which stimulates clonal proliferation and differentiation of various types of blood and tissue cells. It is considered one of the haematopoietic colony-stimulating factors. Synonym: multi-CSF Acronym: IL-3 (12 Dec 1998) |
| natural killer cell stimulating factor | <cytokine> A 75 kD heterodimeric cytokine composed of disulfide-bonded 40 kD and 35 kD subunits that was originally identified by its ability to induce cytotoxic effector cells in synergy with less than optimal concentrations of interleukin-2. It is released by macrophages in response to infection and promotes the activation of cell-mediated immunity. Specifically, IL-12 triggers the maturation of Thl CD4 cells, specific cytotoxic T-lymphocyte responses and an increase in the activity of NK cells and consequently, it is the initiator of cell-mediated immunity. It enhances the lytic activity of NK cells, induces interferon production, stimulates the proliferation of activated T-cells and NK cells. Is secreted by human B lymphoblastoid cells (NC 37). May play a role in controlling immunoglobulin isotype selection as it also inhibits IgE synthesis (even in the presence of anti-IFN monoclonal antibody) and as a growth factor for activated CD4+ and CD8+ T-cells independently of interleukin-2, and for CD56+ NK cells but not resting peripheral blood mononuclear cells or resting or activated tonsillar B-cells. It is likely that interleukin 12 has a major role in protective immunity against viruses and is under study as an immunotherapy in HIV infection. Formerly referred to as cytotoxic lymphocyte maturation factor. Acronym: IL-12 (12 Dec 1998) |